Evidence map›Paper›PMID 32563280›Full record

ReviewThe Lancet. Infectious diseases2020

Recent successes in therapeutics for Ebola virus disease: no time for complacency.

Patrick L Iversen, Christopher D Kane, Xiankun Zeng, Rekha G Panchal, Travis K Warren, Sheli R Radoshitzky, Jens H Kuhn, Rajini R Mudhasani, Christopher L Cooper, Amy C Shurtleff and 16 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Disruption of Ebola NPJournal of molecular biology · 2023
    Article
  7. Article
  8. Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 1 country.

Patrick L IversenUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Christopher D KaneUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Xiankun ZengUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Rekha G PanchalUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Travis K WarrenUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Sheli R RadoshitzkyUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Jens H KuhnIntegrated Research Facility at Fort Detrick, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
Rajini R MudhasaniUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Christopher L CooperUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Amy C ShurtleffUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Farooq NasarUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Melek Me SunayUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Allen J DuplantierUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Brett P EatonUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Elizabeth E ZumbrunUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Sandra L BixlerUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Shannon MartinUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
J Matthew MeinigUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Chih-Yuan ChiangUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Mariano Sanchez-LockhartUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Gustavo F PalaciosUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Jeffrey R KugelmanUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Karen A MartinsUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Margaret L PittUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Ian CrozierIntegrated Research Facility at Fort Detrick, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
David L SaundersUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA. Electronic address: david.l.saunders.mil@mail.mil.
United States Army Medical Research Institute of Infectious Diseases · USFrederick National Laboratory for Cancer Research · USNational Institute of Allergy and Infectious Diseases · US

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS HHSN272200700016INIAID NIH HHS HHSN272201800013C
6 · The paper itself

Abstract

The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.

Indexed as

Antibodies, MonoclonalEbola VaccinesHemorrhagic Fever, EbolaHumansPost-Exposure ProphylaxisAntibodies, MonoclonalEbola Vaccines

Identifiers

PMID32563280
PMCPMC7302789
OpenAlexW3036370467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.